Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21631984 | 0.89 | KDM4E (0.44) | AKR1B1KMT2AFFAR1GAAKDM4E | |
| SCHEMBL21956246 | 0.83 | AKR1B1 (0.41) | AKR1B1KMT2AFFAR1MGAMGAA | |
| SCHEMBL21632173 | 0.81 | MEN1 (0.43) | KMT2AFFAR1MEN1 | |
| SCHEMBL25324001 | 0.79 | KMT2A (0.41) | KMT2AFFAR1KDM4E | |
| SCHEMBL21656577 | 0.77 | CTSL (0.36) | KMT2AGAA | |
| SCHEMBL6074933 | 0.76 | AKR1B1 (0.50) | AKR1B1KMT2AMEN1CACNA2D1CACNA1B | |
| SCHEMBL21631961 | 0.76 | KMT2A (0.51) | KMT2AFFAR1MEN1CACNA2D1CACNA1B | |
| SCHEMBL11159728 | 0.75 | CACNA2D1 (0.40) | AKR1B1KMT2AMEN1CACNA2D1CACNA1B | |
| SCHEMBL7353921 | 0.75 | ALDH1A1 (0.38) | AKR1B1KMT2AMEN1 | |
| SCHEMBL11156376 | 0.75 | CACNA2D1 (0.40) | AKR1B1KMT2AMGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | AKR1B1 3165/4885KMT2A 921/4885FFAR1 781/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | AKR1B1 3165/4885KMT2A 921/4885FFAR1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.